Increased plasma DYRK1A with aging may protect against neurodegenerative diseases.

Autor: Delabar JM; Paris Brain Institute (ICM), Centre National de la Recherche Scientifique (CNRS) UMR 7225, INSERM U1127, Sorbonne Université, Hôpital de la Pitié-Salpêtrière, Paris, 75013, France. jeanmaurice.delabar@icm-institute.org., Lagarde J; Department of Neurology of Memory and Language, GHU Paris Psychiatrie & Neurosciences, Hôpital Sainte Anne, Paris, 75013, France.; Paris-Saclay University, BioMaps, Service Hospitalier Frédéric Joliot CEA, CNRS, Inserm, Orsay, 91400, France., Fructuoso M; Paris Brain Institute (ICM), Centre National de la Recherche Scientifique (CNRS) UMR 7225, INSERM U1127, Sorbonne Université, Hôpital de la Pitié-Salpêtrière, Paris, 75013, France., Mohammad A; Paris Brain Institute (ICM), Centre National de la Recherche Scientifique (CNRS) UMR 7225, INSERM U1127, Sorbonne Université, Hôpital de la Pitié-Salpêtrière, Paris, 75013, France., Bottlaender M; Paris-Saclay University, BioMaps, Service Hospitalier Frédéric Joliot CEA, CNRS, Inserm, Orsay, 91400, France., Doran E; School of Medicine, Department of Pediatrics, University of California, Irvine, CA, 92697, USA., Lott I; School of Medicine, Department of Pediatrics, University of California, Irvine, CA, 92697, USA., Rivals I; Equipe de Statistique Appliquée, ESPCI Paris, INSERM, UMRS 1158 Neurophysiologie Respiratoire Expérimentale et Clinique, PSL Research University, Paris, 75005, France., Schmitt FA; Department of Neurology, University of Kentucky, Lexington, KY, 40506, USA., Head E; Department of Neurology, University of Kentucky, Lexington, KY, 40506, USA.; Department of Pathology and Laboratory Medicine, University of California, Irvine, CA, 92697, USA., Sarazin M; Department of Neurology of Memory and Language, GHU Paris Psychiatrie & Neurosciences, Hôpital Sainte Anne, Paris, 75013, France.; Paris-Saclay University, BioMaps, Service Hospitalier Frédéric Joliot CEA, CNRS, Inserm, Orsay, 91400, France., Potier MC; Paris Brain Institute (ICM), Centre National de la Recherche Scientifique (CNRS) UMR 7225, INSERM U1127, Sorbonne Université, Hôpital de la Pitié-Salpêtrière, Paris, 75013, France. marie-claude.potier@icm-institute.org.
Jazyk: angličtina
Zdroj: Translational psychiatry [Transl Psychiatry] 2023 Apr 04; Vol. 13 (1), pp. 111. Date of Electronic Publication: 2023 Apr 04.
DOI: 10.1038/s41398-023-02419-0
Abstrakt: Early markers are needed for more effective prevention of Alzheimer's disease. We previously showed that individuals with Alzheimer's disease have decreased plasma DYRK1A levels compared to controls. We assessed DYRK1A in the plasma of cognitively healthy elderly volunteers, individuals with either Alzheimer's disease (AD), tauopathies or Down syndrome (DS), and in lymphoblastoids from individuals with DS. DYRK1A levels were inversely correlated with brain amyloid β burden in asymptomatic elderly individuals and AD patients. Low DYRK1A levels were also detected in patients with tauopathies. Individuals with DS had higher DYRK1A levels than controls, although levels were lower in individuals with DS and with dementia. These data suggest that plasma DYRK1A levels could be used for early detection of at risk individuals of AD and for early detection of AD. We hypothesize that lack of increase of DYRK1A at middle age (40-50 years) could be a warning before the cognitive decline, reflecting increased risk for AD.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: